SrasV1, PascalFrancis, Curation, bibRecord, 000607

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

Identifieur interne : 000607 ( PascalFrancis/Curation ); précédent : 000606; suivant : 000608

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

Auteurs : LANYING DU [République populaire de Chine, Hong Kong] ; GUANGYU ZHAO [République populaire de Chine] ; YUXIAN HE [République populaire de Chine, États-Unis] ; YAN GUO [République populaire de Chine] ; Bo-Jian Zheng [Hong Kong] ; SHIBO JIANG [États-Unis] ; YUSEN ZHOU [République populaire de Chine]

Source :

Vaccine [ 0264-410X ] ; 2007.

RBID : Pascal:07-0189645

Descripteurs français

Pascal (Inist)
- Protéine, Immunoprotection, Modèle animal, Sousunité, Vaccin, Syndrome respiratoire aigu sévère.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Animal model, Immunoprotection, Protein, Severe acute respiratory syndrome, Subunit, Vaccine.

Abstract

Development of effective vaccines against severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is still a priority in prevention of re-emergence of SARS. Our previous studies have shown that the receptor-binding domain (RBD) of SARS-CoV spike (S) protein elicits highly potent neutralizing antibody responses in the immunized animals. But it is unknown whether RBD can also induce protective immunity in an animal model, a key aspect for vaccine development. In this study, BALB/c mice were vaccinated intramuscularly (i.m.) with 10 μg of RBD-Fc (RBD fused with human IgG1 Fc) and boosted twice at 3-week intervals and one more time at 12th month. Humoral immune responses of vaccinated mice were investigated for up to 12 months at a 1-month interval and the neutralizing titers of produced antibodies were reported at months 0, 3, 6 and 12 post-vaccination. Mice were challenged with the homologous strain of SARS-CoV 5 days after the last boost, and sacrificed 5 days after the challenge. Mouse lung tissues were collected for detection of viral load, virus replication and histopathological effects. Our results showed that RBD-Fc vaccination induced high titer of S-specific antibodies with long-term and potent SARS-CoV neutralizing activity. Four of five vaccinated mice were protected from subsequent SARS-CoV challenge because no significant virus replication, and no obvious histopathological changes were found in the lung tissues of the vaccinated mice challenged with SARS-CoV. Only one vaccinated mouse had mild alveolar damage in the lung tissues. In contrast, high copies of SARS-CoV RNA and virus replication were detected, and pathological changes were observed in the lung tissues of the control mice. In conclusion, our findings suggest that RBD, which can induce protective antibodies to SARS-CoV, may be further developed as a safe and effective SARS subunit vaccine.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 25`
A06				`@2 15`
A08	`01`	`1`	`ENG`	`@1 Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model`
A11	`01`	`1`		`@1 LANYING DU`
A11	`02`	`1`		`@1 GUANGYU ZHAO`
A11	`03`	`1`		`@1 YUXIAN HE`
A11	`04`	`1`		`@1 YAN GUO`
A11	`05`	`1`		`@1 ZHENG (Bo-Jian)`
A11	`06`	`1`		`@1 SHIBO JIANG`
A11	`07`	`1`		`@1 YUSEN ZHOU`
A14	`01`			`@1 State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology @2 Beijing 100071 @3 CHN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 7 aut.`
A14	`02`			`@1 Department of Microbiology, The University of Hong Kong @2 Pokfulam @3 HKG @Z 1 aut. @Z 5 aut.`
A14	`03`			`@1 Lindsley F. Kimball Research Institute, The New York Blood Center @2 New York, NY 10021 @3 USA @Z 3 aut. @Z 6 aut.`
A20				`@1 2832-2838`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000145626990100`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 41 ref.`
A47	`01`	`1`		`@0 07-0189645`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Development of effective vaccines against severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is still a priority in prevention of re-emergence of SARS. Our previous studies have shown that the receptor-binding domain (RBD) of SARS-CoV spike (S) protein elicits highly potent neutralizing antibody responses in the immunized animals. But it is unknown whether RBD can also induce protective immunity in an animal model, a key aspect for vaccine development. In this study, BALB/c mice were vaccinated intramuscularly (i.m.) with 10 μg of RBD-Fc (RBD fused with human IgG1 Fc) and boosted twice at 3-week intervals and one more time at 12th month. Humoral immune responses of vaccinated mice were investigated for up to 12 months at a 1-month interval and the neutralizing titers of produced antibodies were reported at months 0, 3, 6 and 12 post-vaccination. Mice were challenged with the homologous strain of SARS-CoV 5 days after the last boost, and sacrificed 5 days after the challenge. Mouse lung tissues were collected for detection of viral load, virus replication and histopathological effects. Our results showed that RBD-Fc vaccination induced high titer of S-specific antibodies with long-term and potent SARS-CoV neutralizing activity. Four of five vaccinated mice were protected from subsequent SARS-CoV challenge because no significant virus replication, and no obvious histopathological changes were found in the lung tissues of the vaccinated mice challenged with SARS-CoV. Only one vaccinated mouse had mild alveolar damage in the lung tissues. In contrast, high copies of SARS-CoV RNA and virus replication were detected, and pathological changes were observed in the lung tissues of the control mice. In conclusion, our findings suggest that RBD, which can induce protective antibodies to SARS-CoV, may be further developed as a safe and effective SARS subunit vaccine.
C02	`01`	`X`		`@0 002A05F04`
C03	`01`	`X`	`FRE`	`@0 Protéine @5 05`
C03	`01`	`X`	`ENG`	`@0 Protein @5 05`
C03	`01`	`X`	`SPA`	`@0 Proteína @5 05`
C03	`02`	`X`	`FRE`	`@0 Immunoprotection @5 06`
C03	`02`	`X`	`ENG`	`@0 Immunoprotection @5 06`
C03	`02`	`X`	`SPA`	`@0 Inmunoprotección @5 06`
C03	`03`	`X`	`FRE`	`@0 Modèle animal @5 07`
C03	`03`	`X`	`ENG`	`@0 Animal model @5 07`
C03	`03`	`X`	`SPA`	`@0 Modelo animal @5 07`
C03	`04`	`X`	`FRE`	`@0 Sousunité @5 08`
C03	`04`	`X`	`ENG`	`@0 Subunit @5 08`
C03	`04`	`X`	`SPA`	`@0 Subunitad @5 08`
C03	`05`	`X`	`FRE`	`@0 Vaccin @5 09`
C03	`05`	`X`	`ENG`	`@0 Vaccine @5 09`
C03	`05`	`X`	`SPA`	`@0 Vacuna @5 09`
C03	`06`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 14`
C03	`06`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 14`
C03	`06`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 14`
C07	`01`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 13`
C07	`01`	`X`	`ENG`	`@0 Respiratory disease @5 13`
C07	`01`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 13`
C07	`02`	`X`	`FRE`	`@0 Virose`
C07	`02`	`X`	`ENG`	`@0 Viral disease`
C07	`02`	`X`	`SPA`	`@0 Virosis`
C07	`03`	`X`	`FRE`	`@0 Infection`
C07	`03`	`X`	`ENG`	`@0 Infection`
C07	`03`	`X`	`SPA`	`@0 Infección`
C07	`04`	`X`	`FRE`	`@0 Poumon pathologie @5 16`
C07	`04`	`X`	`ENG`	`@0 Lung disease @5 16`
C07	`04`	`X`	`SPA`	`@0 Pulmón patología @5 16`
N21				`@1 128`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000382

Links to Exploration step

Pascal:07-0189645

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</title>
<author><name sortKey="Lanying Du" sort="Lanying Du" uniqKey="Lanying Du" last="Lanying Du">LANYING DU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The University of Hong Kong</s1>
<s2>Pokfulam</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Guangyu Zhao" sort="Guangyu Zhao" uniqKey="Guangyu Zhao" last="Guangyu Zhao">GUANGYU ZHAO</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author><name sortKey="Yuxian He" sort="Yuxian He" uniqKey="Yuxian He" last="Yuxian He">YUXIAN HE</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Lindsley F. Kimball Research Institute, The New York Blood Center</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Yan Guo" sort="Yan Guo" uniqKey="Yan Guo" last="Yan Guo">YAN GUO</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The University of Hong Kong</s1>
<s2>Pokfulam</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Shibo Jiang" sort="Shibo Jiang" uniqKey="Shibo Jiang" last="Shibo Jiang">SHIBO JIANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Lindsley F. Kimball Research Institute, The New York Blood Center</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Yusen Zhou" sort="Yusen Zhou" uniqKey="Yusen Zhou" last="Yusen Zhou">YUSEN ZHOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0189645</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0189645 INIST</idno>
<idno type="RBID">Pascal:07-0189645</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000382</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000607</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</title>
<author><name sortKey="Lanying Du" sort="Lanying Du" uniqKey="Lanying Du" last="Lanying Du">LANYING DU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The University of Hong Kong</s1>
<s2>Pokfulam</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Guangyu Zhao" sort="Guangyu Zhao" uniqKey="Guangyu Zhao" last="Guangyu Zhao">GUANGYU ZHAO</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author><name sortKey="Yuxian He" sort="Yuxian He" uniqKey="Yuxian He" last="Yuxian He">YUXIAN HE</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Lindsley F. Kimball Research Institute, The New York Blood Center</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Yan Guo" sort="Yan Guo" uniqKey="Yan Guo" last="Yan Guo">YAN GUO</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Microbiology, The University of Hong Kong</s1>
<s2>Pokfulam</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Shibo Jiang" sort="Shibo Jiang" uniqKey="Shibo Jiang" last="Shibo Jiang">SHIBO JIANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Lindsley F. Kimball Research Institute, The New York Blood Center</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Yusen Zhou" sort="Yusen Zhou" uniqKey="Yusen Zhou" last="Yusen Zhou">YUSEN ZHOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term>
<term>Immunoprotection</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome</term>
<term>Subunit</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Protéine</term>
<term>Immunoprotection</term>
<term>Modèle animal</term>
<term>Sousunité</term>
<term>Vaccin</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Development of effective vaccines against severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is still a priority in prevention of re-emergence of SARS. Our previous studies have shown that the receptor-binding domain (RBD) of SARS-CoV spike (S) protein elicits highly potent neutralizing antibody responses in the immunized animals. But it is unknown whether RBD can also induce protective immunity in an animal model, a key aspect for vaccine development. In this study, BALB/c mice were vaccinated intramuscularly (i.m.) with 10 μg of RBD-Fc (RBD fused with human IgG1 Fc) and boosted twice at 3-week intervals and one more time at 12th month. Humoral immune responses of vaccinated mice were investigated for up to 12 months at a 1-month interval and the neutralizing titers of produced antibodies were reported at months 0, 3, 6 and 12 post-vaccination. Mice were challenged with the homologous strain of SARS-CoV 5 days after the last boost, and sacrificed 5 days after the challenge. Mouse lung tissues were collected for detection of viral load, virus replication and histopathological effects. Our results showed that RBD-Fc vaccination induced high titer of S-specific antibodies with long-term and potent SARS-CoV neutralizing activity. Four of five vaccinated mice were protected from subsequent SARS-CoV challenge because no significant virus replication, and no obvious histopathological changes were found in the lung tissues of the vaccinated mice challenged with SARS-CoV. Only one vaccinated mouse had mild alveolar damage in the lung tissues. In contrast, high copies of SARS-CoV RNA and virus replication were detected, and pathological changes were observed in the lung tissues of the control mice. In conclusion, our findings suggest that RBD, which can induce protective antibodies to SARS-CoV, may be further developed as a safe and effective SARS subunit vaccine.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>15</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LANYING DU</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GUANGYU ZHAO</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>YUXIAN HE</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>YAN GUO</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ZHENG (Bo-Jian)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SHIBO JIANG</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>YUSEN ZHOU</s1>
</fA11>
<fA14 i1="01"><s1>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology & Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Microbiology, The University of Hong Kong</s1>
<s2>Pokfulam</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Lindsley F. Kimball Research Institute, The New York Blood Center</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>2832-2838</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000145626990100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>41 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0189645</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Development of effective vaccines against severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is still a priority in prevention of re-emergence of SARS. Our previous studies have shown that the receptor-binding domain (RBD) of SARS-CoV spike (S) protein elicits highly potent neutralizing antibody responses in the immunized animals. But it is unknown whether RBD can also induce protective immunity in an animal model, a key aspect for vaccine development. In this study, BALB/c mice were vaccinated intramuscularly (i.m.) with 10 μg of RBD-Fc (RBD fused with human IgG1 Fc) and boosted twice at 3-week intervals and one more time at 12th month. Humoral immune responses of vaccinated mice were investigated for up to 12 months at a 1-month interval and the neutralizing titers of produced antibodies were reported at months 0, 3, 6 and 12 post-vaccination. Mice were challenged with the homologous strain of SARS-CoV 5 days after the last boost, and sacrificed 5 days after the challenge. Mouse lung tissues were collected for detection of viral load, virus replication and histopathological effects. Our results showed that RBD-Fc vaccination induced high titer of S-specific antibodies with long-term and potent SARS-CoV neutralizing activity. Four of five vaccinated mice were protected from subsequent SARS-CoV challenge because no significant virus replication, and no obvious histopathological changes were found in the lung tissues of the vaccinated mice challenged with SARS-CoV. Only one vaccinated mouse had mild alveolar damage in the lung tissues. In contrast, high copies of SARS-CoV RNA and virus replication were detected, and pathological changes were observed in the lung tissues of the control mice. In conclusion, our findings suggest that RBD, which can induce protective antibodies to SARS-CoV, may be further developed as a safe and effective SARS subunit vaccine.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Protéine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Protein</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Proteína</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Immunoprotection</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Immunoprotection</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inmunoprotección</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Modèle animal</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Animal model</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Modelo animal</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sousunité</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Subunit</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Subunitad</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21><s1>128</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000607 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000607 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0189645
   |texte=   Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri